Aptinyx Inc. (APTX)

NASDAQ: APTX · IEX Real-Time Price · USD
0.420
-0.010 (-2.33%)
At close: Sep 23, 2022 4:00 PM
0.430
+0.010 (2.381%)
After-hours: Sep 23, 2022 7:04 PM EDT
-2.33%
Market Cap 28.44M
Revenue (ttm) n/a
Net Income (ttm) -78.34M
Shares Out 67.72M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 651,735
Open 0.420
Previous Close 0.430
Day's Range 0.400 - 0.430
52-Week Range 0.330 - 3.760
Beta 1.28
Analysts Buy
Price Target 2.55 (+507.1%)
Earnings Date Nov 7, 2022

About APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical t... [Read more...]

Industry Biotechnology
IPO Date Jun 21, 2018
Employees 40
Stock Exchange NASDAQ
Ticker Symbol APTX
Full Company Profile

Financial Performance

In 2021, Aptinyx's revenue was $1,000,000, a decrease of -36.06% compared to the previous year's $1.56 million. Losses were -$74.89 million, 49.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for APTX stock is "Buy." The 12-month stock price forecast is 2.55, which is an increase of 507.14% from the latest price.

Price Target
$2.55
(507.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease ...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 weeks ago - Business Wire

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

1 month ago - Zacks Investment Research

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

1 month ago - Business Wire

Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

1 month ago - Business Wire

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 months ago - Business Wire

All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy

Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

3 months ago - Business Wire

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

4 months ago - Business Wire

Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported...

4 months ago - Business Wire

Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NY...

EVANSTON, Ill.,--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, tod...

5 months ago - Business Wire

Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

5 months ago - Zacks Investment Research

Aptinyx Shares Tank On Disappointed Data From Mid-Stage Diabetic Peripheral Neuropathy Study

Aptinyx Inc (NASDAQ: APTX) shares are plunging after results from a Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN).  NYX-2925 did not achieve statistically sign...

5 months ago - Benzinga

Aptinyx's stock falls 48% after drug fails in Phase 2b trial

Shares of Aptinyx Inc. APTX, -4.49% tumbled 48.7% in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primary ...

5 months ago - Market Watch

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

7 Biotech Stocks to Buy With Key Catalysts for April

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belon...

Other symbols: ALNYBMYBPMCCHRSHCMTARS
5 months ago - InvestorPlace

Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?

Here is how Aptinyx Inc. (APTX) and Doximity (DOCS) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?

Here is how Aptinyx Inc. (APTX) and ICU Medical (ICUI) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Aptinyx to Participate in the 42nd Annual Cowen Health Care Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Deve...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will...

7 months ago - Business Wire